Caroline Seymour

Low platelet counts were associated with a greater severity of disease-related symptoms compared with low hemoglobin in patients with myelofibrosis, according to findings from a retrospective analysis of the phase 3 PERSIST-1 and PAC203 trials.

The European Commission has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition, for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

The FDA has accepted a new drug application for EVG-001, a kit for the preparation of Gallium-68 DOTATOC injection, a radiopharmaceutical approved for imaging of neuroendocrine tumors using positron emission tomography.

The addition of magrolimab to azacitidine and venetoclax produced high complete response rates and was well tolerated as first-line therapy in patients with high-risk de novo and secondary acute myeloid leukemia regardless of TP53 mutation status.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

The phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia will continue as planned without modifications following a recommendation from the Independent Data Monitoring Committee.

The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Treatment with lutetium Lu 177 vipivotide tetraxetan led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival following treatment with an androgen receptor pathway inhibitor in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Olaparib plus durvalumab and bevacizumab led to prolonged survival and disease control without causing additive toxicity in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer.

The FDA has granted a fast track designation to pelareorep for use in combination with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of patients with advanced or metastatic pancreatic cancer.

Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer.

The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of nivolumab plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.

The score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–small cell lung cancer treated with single-agent immunotherapy, regardless of performance status.

The European Commission has approved zanubrutinib for the treatment of adult patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia.

The FDA has granted an orphan drug designation to the highly specific HDAC6 inhibitor AVS100 for the treatment of patients with stage IIB to IV melanoma.

The Center for Drug Evaluation of the China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab plus docetaxel for patients with locally advanced or metastatic non–small cell lung cancer who failed to respond to a prior PD-(L)1 inhibitor plus platinum-based doublet chemotherapy.

The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

The European Medicines Agency’s CHMP has recommended the approval of trastuzumab deruxtecan as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

Chung-Han Lee, MD, PhD, outlines common clinical trial end points in renal cell carcinoma and those that may provide a more complete picture of a drug’s activity, particularly as the standard of care evolves.

Regorafenib plus ipilimumab and nivolumab led to encouraging survival and responses in approximately half of patients with microsatellite stable, non–liver metastatic colorectal cancer who progressed on prior chemotherapy.

The combination of nivolumab and ipilimumab led to significant improvements in survival vs sunitinib in patients with intermediate- and poor-risk renal cell carcinoma with sarcomatoid features.

The FDA has granted a breakthrough therapy designation to elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA has granted an orphan drug designation to OTX-2002 for the treatment of patients with hepatocellular carcinoma.

The first patient in the chronic lymphocytic leukemia cohort has been dosed in the phase 1 COVALENT-101 trial, which is evaluating the first-in-class covalent menin inhibitor BMF-219.

In a special OncLive video program, The Board, D. Ross Camidge, MD, PhD, led a discussion regarding key abstracts that were presented during the 2022 ESMO Congress in non–small cell lung cancer.

Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.